Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06056895
Status:
RECRUITING
Last Update Posted:
2024-03-20
First Post:
2023-09-20
Brief Title:
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-L1 Refractory Merkel Cell Carcinoma
Sponsor:
University of Washington
Organization:
University of Washington
Study Overview
Official Title:
A Proof-of-Concept Study of Combination Therapy With INCMGA00012 Anti-PD-1 INCAGN02385 Anti-LAG-3 and INCAGN02390 Anti-TIM-3 in Participants With Advanced or Metastatic PD-L1 Refractory Merkel Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRICK-MCC
Brief Summary:
This phase II trial tests how well a combination of three immunotherapy drugs work for patients with Merkel cell carcinoma that has spread to lymph nodes andor distant parts of the body and cannot be treated with surgery advanced or metastatic MCC and grew despite prior PD-L1 therapy The three drugs INCMGA00012 retifanlimab anti-PD-1 INCAGN02385 tuparstobart anti-LAG-3 and INCAGN02390 verzistobart anti-TIM-3 are monoclonal antibodies given periodically via IV to reactivate the bodys immune system to attack the cancer This combination may stop tumor growth if tumors have grown despite anti-PD-L1 therapy alone
Detailed Description:
OUTLINE
All patients receive the same investigational drug combination
SCREENING Patients undergo history and physical examination adverse event assessment safety and eligibility labs radiologic evaluation with computed tomography CTmagnetic resonance imaging MRI and complete informed consent
INDUCTION PHASE Patients receive anti-LAG-3 and anti-TIM-3 intravenously IV every 2 weeks along with retifanlimab anti-PD-1 IV every 4 weeks along with clinical visit physical examination and labs for safety Treatment continues for up to day 169 in the absence of disease progression or unacceptable toxicity Patients undergo CTMRI every 8 weeks Research tumor biopsies will be obtained on day 1 and day 15 unless unsafe and unfeasible Research blood draws will occur at day 1 day 15 and periodically throughout Induction Phase
MAINTENANCE PHASE Patients receive all three drugs IV every 6 weeks along with clinical visit physical examination and labs for safety Treatment continues for up to day 715 in the absence of disease progression or unacceptable toxicity Patients undergo CTMRI every 12 weeks Research blood sample collection will continue periodically
Patients with progressive disease per investigator evaluation will stop receiving therapy Research blood and tumor biopsies will be obtained at time of progression if safe and feasible
Upon completion of study treatment day 715 or sooner for disease progression safety visits occur at 30 and 90 days Follow up for long term outcomes continues every 6 months for up to 5 years
All patients receive the same investigational drug combination
SCREENING Patients undergo history and physical examination adverse event assessment safety and eligibility labs radiologic evaluation with computed tomography CTmagnetic resonance imaging MRI and complete informed consent
INDUCTION PHASE Patients receive anti-LAG-3 and anti-TIM-3 intravenously IV every 2 weeks along with retifanlimab anti-PD-1 IV every 4 weeks along with clinical visit physical examination and labs for safety Treatment continues for up to day 169 in the absence of disease progression or unacceptable toxicity Patients undergo CTMRI every 8 weeks Research tumor biopsies will be obtained on day 1 and day 15 unless unsafe and unfeasible Research blood draws will occur at day 1 day 15 and periodically throughout Induction Phase
MAINTENANCE PHASE Patients receive all three drugs IV every 6 weeks along with clinical visit physical examination and labs for safety Treatment continues for up to day 715 in the absence of disease progression or unacceptable toxicity Patients undergo CTMRI every 12 weeks Research blood sample collection will continue periodically
Patients with progressive disease per investigator evaluation will stop receiving therapy Research blood and tumor biopsies will be obtained at time of progression if safe and feasible
Upon completion of study treatment day 715 or sooner for disease progression safety visits occur at 30 and 90 days Follow up for long term outcomes continues every 6 months for up to 5 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2023-06784 | REGISTRY | None | None |
| FHIRB0020193 | OTHER | Fred HutchUniversity of Washington Cancer Consortium | None |